AtG can help when standard therapy fails
How it works
Determine plasma levels of RF-1 in metastatic kidney patients
Selection of patients with higher RF-1 levels
Treatment with RF-1 inhibitor
With our technology we will improve the lives of patients affected by cancer therapeutic resistance
Fills a medical need
Fast prediction of patients response
New tool for clinical decision-making processes to be made regarding treatments.
Our technology could be applied to other tumors too
First-in-Class anti-cancer treatment to prevent anti-angiogenics resistance.
HIT to LEAD
RF-1 Companion Dx
Diagnostic test to determine which patients will benefit from RF-1 inhibitor (AtG 101), thus delivering a more personalized treatment.
Diagnostic test to determine which patients will benefit from anti-angiogenic inhibitors, thus delivering a more personalized treatment.